CD9 Antibody

What is CD9 and why is it an important research target?

CD9 is a type IV transmembrane glycoprotein belonging to the tetraspanin superfamily with four transmembrane domains. Its importance in research stems from multiple biological functions, including:

• Cell-cell adhesion, particularly in pre-B cells

• Signal transduction mediated through interactions with low molecular weight GTP binding proteins

• Major component of platelet cell surface structures

• Key marker for exosomes, along with CD63 and CD81

• Critical roles in sperm-egg fusion and fertilization

• Regulation of myotube fusion during muscle regeneration

CD9 is widely expressed across multiple cell types including early B cells, eosinophils, basophils, activated T cells, platelets, and also appears on non-T acute lymphoblastic leukemia cells and some acute myeloid and chronic lymphoid leukemia cells . Its broad expression pattern and involvement in diverse cellular processes make it a valuable research target.

Selection should be based on several key criteria:

• Target species: Ensure antibody reactivity with your experimental organism (human, mouse, rat, etc.)

• Application compatibility: Verify the antibody has been validated for your specific application

• Epitope location: Different clones recognize different epitopes on CD9

  • Clone 2310.9 recognizes human CD9 tetraspanin

  • Clone EM-04 is validated for mouse CD9

  • Clone 209306 is validated for human CD9

• Format requirements: Consider conjugated vs. unconjugated formats based on experimental design

• Isotype considerations: For example, IgG1 vs. IgG2a/b can affect FcR binding

For multi-parameter studies, consider validated antibody combinations and potential spectral overlap if using fluorochrome-conjugated antibodies.

What controls are essential when using CD9 antibodies?

Proper experimental controls are critical for CD9 antibody applications:

• Isotype controls: Use matching isotype antibodies to account for non-specific binding

  • For CD9 clone 2310.9, use Isotype Control, Monoclonal Mouse IgG1 Kappa

  • For IgG2b clones, use appropriate IgG2b isotype controls

• Negative cell controls: Include CD9-negative cell lines (e.g., U937 human histiocytic lymphoma cell line)

• Positive cell controls: Use known CD9-expressing cells (e.g., platelets, RPMI 8226 human multiple myeloma cell line)

• Peptide competition: For polyclonal antibodies, perform peptide blocking to confirm specificity

• Knockout/knockdown validation: When available, use CD9 knockout or knockdown samples

Example from the literature: "Human peripheral blood platelets were stained with Mouse Anti-Human CD9 Monoclonal Antibody (Catalog # MAB25292) or isotype control antibody (Catalog # MAB0041) followed by anti-Mouse IgG PE-conjugated Secondary Antibody" .

How can researchers optimize CD9 detection in flow cytometry?

Flow cytometry optimization for CD9 requires careful consideration of:

• Antibody titration: Determine optimal concentration through titration experiments

  • The biphasic dose-response curve observed in some studies indicates optimal antibody concentrations typically fall between 10-100 nM

  • Over-saturation can reduce signal quality

• Sample preparation:

  • For exosome analysis: Standardized ultracentrifugation or size-exclusion chromatography

  • For cellular analysis: Proper fixation that preserves epitope accessibility

  • Avoid aggregations by centrifuging antibodies at 100,000g for 1 hour prior to use

• Multicolor panel design:

  • CD9 can be effectively paired with other markers like CD41 (Integrin alpha 2b)

  • Consider spectral overlap when selecting fluorochromes

• Gating strategy:

  • For platelets: "Human peripheral blood platelets were stained with Mouse anti-Human CD9 followed by anti-Mouse IgG PE-conjugated Secondary Antibody and Mouse anti-Human Integrin alpha 2b/CD41 APC-conjugated antibody"

How can CD9 antibodies be used to study exosome biology?

CD9 is one of the most common exosome markers along with CD63 and CD81. For exosome research:

• Exosome isolation validation:

  • Use western blotting with anti-CD9 to confirm exosome preparation quality

  • "All four exosome samples and their corresponding cell lines were used for validation... supernatant from the pelleted exosomes was used as a control"

• Quantitative analysis:

  • Flow cytometry of exosome-coated beads using fluorescently-labeled CD9 antibodies

  • Use multiple tetraspanin markers (CD9, CD63, CD81) for comprehensive characterization

• Immunoaffinity capture:

  • CD9 antibodies can be coupled to magnetic beads for exosome isolation

  • Consider potential bias in exosome subpopulation selection

• Expression level considerations:

  • "Tetraspanins are broadly expressed on many cell types and can therefore be detected on many types of exosomes, but their expression levels vary depending on the cell type of origin"

What are the mechanistic implications of CD9 antibody binding to cell surfaces?

CD9 antibody binding can induce functional effects that must be considered in experimental design:

• Activation effects:

  • "Antibody cross-linking of the tetraspanin protein CD9 stimulates the degranulation of platelets and eosinophils"

  • In transfected RBL-2H3 cells, "Intact immunoglobulin G1 (IgG1) antibodies activated transfected cells whereas F(ab′)2 fragments of antibody and an intact IgG2a did not"

• Signaling pathway interactions:

  • CD9 cross-linking can interact with FcεRI signaling

  • "CD9 forms complexes with FcεRI in the absence of anti-CD9 mAbs. Activation of RBL cells by the polyvalent antigen, DNP-HSA, increased the amounts of CD9 associated with FcεRI"

• Format-dependent effects:

  • Whole IgG vs. F(ab′)2 fragments can produce dramatically different cellular responses

  • "F(ab′)2 fragments of two mAb, ALMA 1 and ALMA 11, failed to stimulate degranulation although they retained the ability to bind to cells transfected with CD9"

How do different detergents affect CD9 antibody immunoprecipitation efficiency?

The choice of detergent is critical when immunoprecipitating CD9 and its associated proteins:

• Mild detergent conditions:

  • "Immunoprecipitation of FcεRI under mild detergent conditions co-precipitated CD9, suggesting the presence of pre-existing complexes of CD9 and FcεRI"

  • CHAPS (3-[(3-cholamidopropyl)-dimethylammonio]-l-propane sulphanate) at 1% concentration preserves many tetraspanin-protein interactions

• Detergent comparison:

  • CHAPS: Preserves most tetraspanin-tetraspanin interactions

  • Triton X-100: Disrupts most tetraspanin associations

  • Digitonin: Intermediate preservation of complexes

  • Brij series: Variably preserves tetraspanin complexes based on concentration

• Protocol considerations:

  • Temperature during lysis (maintain at 4°C)

  • Inclusion of protease and phosphatase inhibitors

  • Buffer composition (salt concentration can affect complex stability)

How can researchers validate CD9 antibody specificity?

Comprehensive validation strategies include:

• Genetic validation:

  • Testing on CD9 knockout/knockdown cells

  • Comparison across multiple cell types with known CD9 expression levels

• Biochemical validation:

  • Western blot should show a band at approximately 24 kDa under reducing conditions

  • Peptide competition assays for polyclonal antibodies

  • Testing multiple antibody clones targeting different epitopes

• Cross-reactivity testing:

  • Test on closely related tetraspanins (CD81, CD63)

  • Check species cross-reactivity if working with non-human samples

• Application-specific validation:

  • "This antibody has been validated in flow cytometry, immunofluorescence microscopy, and in western blot"

  • Confirm specificity in your specific application before proceeding with experiments

What are common problems when using CD9 antibodies and their solutions?

What special considerations apply when using CD9 antibodies for mechanistic studies?

When using CD9 antibodies to investigate biological mechanisms:

• Potential activation effects:

  • "The anti-CD9 mAb activation curve was biphasic, and supraoptimal antibody concentrations stimulated little or no degranulation"

  • Consider whether antibody binding itself affects the biological process being studied

• Epitope-specific effects:

  • Different epitopes on CD9 can influence binding to partner proteins

  • "The anti-CD9 antibodies recognized adjacent or identical epitopes on the large extracellular domain of CD9"

• Isotype-dependent interactions:

  • "ALMA 1, 11 and ALB 6 (IgG1) all stimulate secretion according to a biphasic dose–response curve, whereas ALMA 3 (IgG2a) had no effect"

  • Consider control experiments with different isotypes

• Concentration-dependent effects:

  • "At peak stimulatory levels of mAb, antibody binding was 100%, with stimulation decreasing as binding remained at saturation levels"

  • Perform careful titration experiments to determine optimal antibody concentrations

How are CD9 antibodies being used in exosome-based diagnostic approaches?

Emerging diagnostic applications include:

• Liquid biopsy development:

  • "An immunogold single extracellular vesicular RNA and protein (Au SERP) biochip to predict responses to immunotherapy in non-small cell lung cancer patients"

  • CD9 antibodies help capture and characterize disease-specific exosomes

• Cerebrospinal fluid analysis:

  • "A Comprehensive Study of Vesicular and Non-Vesicular miRNAs from a Volume of Cerebrospinal Fluid Compatible with Clinical Practice"

  • CD9 antibodies enable exosome isolation from limited clinical samples

• Multi-marker approaches:

  • Combined analysis of CD9 with other exosome markers (CD63, CD81) and cargo proteins

  • "The selected proteins FASN, XPO1, CD9 and PDCD6IP, were tested with ENO1 and GAPDH as controls"

What are the considerations for using CD9 antibodies in therapeutic development?

Research using CD9 antibodies for therapeutic applications should consider:

• Target validation:

  • CD9's role in cell fusion processes may offer therapeutic opportunities

  • "CD9 on pre-B cells may play a role in cell-cell adhesion"

• Delivery platforms:

  • "Targeting Antigen to the Surface of EVs Improves the In-Vivo Immunogenicity of Human and Non-human Adenoviral Vaccines in Mice"

  • CD9 antibodies can help characterize engineered exosomes

• Biomarker applications:

  • "Neutrophil-derived miR-223 as local biomarker of bacterial peritonitis"

  • CD9 antibodies enable isolation of cell-specific exosome populations

• CD9 expression in pathological conditions:

  • "CD9 is also expressed on most non-T acute lymphoblastic leukemia cells and on some acute myeloid and chronic lymphoid leukemia"

  • "CD9 is also considered as metastasis suppressor in solid tumors"